成人伯基特淋巴瘤患者接受CAR T细胞治疗的结局
这项多中心回顾性研究评估了31例复发/难治性伯基特淋巴瘤患者接受CD19 CAR T细胞治疗的真实世界结局。1个月总缓解率为58.0%,完全缓解率41.9%,但6个月完全缓解率仅19.4%;中位无进展生存期2.3个月,中位总生存期6.0个月。结论认为CD19 CAR T细胞治疗在伯基特淋巴瘤中很少能实现长期疾病控制,需进一步研究确定最有效的替代管理策略。
要点
- 31例复发/难治性伯基特淋巴瘤患者接受CD19 CAR T细胞治疗,中位既往治疗线数为3线(范围1-6)。
- 1个月总缓解率58.0%、完全缓解率41.9%,但6个月完全缓解率仅19.4%。
- 中位无进展生存期2.3个月(95%CI 1.0-9.0),中位总生存期6.0个月(95%CI 1.9-11.5)。
核心结论
- CD19 CAR T细胞治疗在伯基特淋巴瘤中很少能实现长期疾病控制。
- 需进一步研究以确定这些患者最有效的替代管理策略。
研究设计与样本
- 多中心、回顾性研究,评估复发/难治性伯基特淋巴瘤患者接受CD19 CAR T细胞治疗的真实世界结局,数据取自病历记录。
- 共31例患者接受CAR T细胞治疗,既往治疗中位数为3线(范围1-6)。
- 患者接受阿基仑赛(n=19)、lisocabtagene maraleucel(n=4)、tisagenlecleucel(n=4)或其他药物(n=4)。
主要发现
- 1级至2级细胞因子释放综合征发生于83.9%的患者(≥3级为65%),1级至2级免疫效应细胞相关神经毒性综合征(ICANS)发生于29%的患者(≥3级为19.4%)。
- 28天死亡率为16.1%,包括1例死于5级ICANS的患者。
- 1个月总缓解率为58.0%,完全缓解(CR)率为41.9%;但6个月CR率仅为19.4%。
- 中位无进展生存期为2.3个月(95%CI 1.0-9.0),中位总生存期为6.0个月(95%CI 1.9-11.5)。
- 3例患者(9.7%)接受了巩固性异基因干细胞移植,但随后均复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T cells after a median of 3 previous therapies (range, 1-6). Patients received axicabtagene ciloleucel (n = 19), lisocabtagene maraleucel (n = 4), tisagenlecleucel (n = 4), or other agents (n = 4). Grade 1 to 2 cytokine release syndrome occurred in 83.9% of patients (grade ≥3, 65%), and grade 1 to 2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 29% of patients (grade ≥3, 19.4%). The 28-day mortality rate was 16.1%, including 1 patient who died from grade 5 ICANS. The overall response rate at 1 month was 58.0% with a complete response (CR) rate of 41.9%; however, the 6-month CR rate was only 19.4%. The median progression-free survival was 2.3 months (95% confidence interval, 1.0-9.0), and the median overall survival was 6.0 months (95% confidence interval, 1.9-11.5). Three patients (9.7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed. In conclusion, CD19 CAR T-cell therapy infrequently delivers long-term disease control in BL. Further investigation is needed to determine the most effective alternative management strategy for these patients.
引用
- Samples L, Sadrzadeh H, Frigault MJ, et al. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025. PMID: 39938007. doi:10.1182/blood.2024026831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。